28th week of 2022 patent applcation highlights part 23 |
Patent application number | Title | Published |
20220220098 | CRYSTAL FORM OF PYRIMIDINE SULFONAMIDE COMPOUND AND PREPARATION METHOD THEREFOR - Disclosed are a Crystal Form (I) of a pyrimidine sulfonamide compound and a preparation method therefor. The present disclosure relates to an application thereof in the preparation of a medicament for treating diseases related to ET | 2022-07-14 |
20220220099 | BENZAMIDE COMPOUND, AND HERBICIDE - It is to provide a novel benzamide compound useful as an active ingredient of a herbicide, the benzamide compound exhibiting a definite weed control effect even in a small amount, having low phytotoxicity to crops, and having high safety in environments, and a herbicide. A compound of the present invention is a compound of formula (II) or a salt thereof. In formula (II), Het is a substituted or unsubstituted five-membered heteroaryl group; R | 2022-07-14 |
20220220100 | PHOTOCHROMIC AND ELECTROCHROMIC DIARYLETHENE COMPOUNDS WITH IMPROVED PHOTOSTABILITY AND SOLUBILITY - A diarylethene compound reversibly convertible under photochromic and electrochromic conditions between a ring-open isomer of Formula (1A) and a ring-closed isomer of Formula (IB) wherein R | 2022-07-14 |
20220220101 | COMPOSITIONS AND METHODS FOR VIRAL SENSITIZATION - Provided are compounds that enhance the efficacy of viruses by increasing spread of the virus in cells, increasing the titer of virus in cells, or increasing the antigen expression from a virus, gene or trans-gene expression from a virus, or virus protein expression in cells. Other uses, compositions and methods of using same are also provided. | 2022-07-14 |
20220220102 | D3 RECEPTOR AGONIST COMPOUNDS; METHODS OF PREPARATION; INTERMEDIATES THEREOF; AND METHODS OF USE THEREOF - Disclosed herein are novel compounds including dopamine D | 2022-07-14 |
20220220103 | CYCLIN-DEPENDENT KINASE INHIBITORS - Described herein are compounds and their pharmaceutically acceptable salts, pharmaceutical compositions thereof, methods of treatment, and medical uses. The compounds described herein are modulators of cyclin-dependent kinases, and are useful in the treatment or alleviation of protein kinase associated disorders, including cancer, infectious diseases, autoimmune diseases, or cardiovascular diseases. | 2022-07-14 |
20220220104 | PYRAZOLOPYRIDINE COMPOUND AS RET INHIBITOR AND APPLICATION THEREOF - Disclosed is a series of pyrazolopyridine compounds, and application thereof in the preparation of RET kinase inhibitors for treatment. Specifically disclosed is the compound represented by formula (I), or a pharmaceutically acceptable salt thereof. | 2022-07-14 |
20220220105 | LIGHT-EMITTING DEVICE, LIGHT-EMITTING APPARATUS, ELECTRONIC DEVICE, AND LIGHTING DEVICE - A light-emitting device with high emission efficiency is provided. The light-emitting device includes a fluorescent substance and a phosphorescent substance or a thermally activated delayed fluorescent material; the fluorescent substance includes a luminophore and five or more protecting groups; the luminophore is a condensed aromatic ring or a condensed heteroaromatic ring; the five or more protecting groups each have any one of an alkyl group having 1 to 10 carbon atoms, a substituted or unsubstituted cycloalkyl group having 3 to 10 carbon atoms, and a trialkylsilyl group having 3 to 12 carbon atoms; the lowest singlet excitation energy level of the fluorescent substance is higher than the lowest triplet excitation energy level of the phosphorescent substance or the thermally activated delayed fluorescent material; and light emission can be obtained from both the phosphorescent substance and the phosphorescent substance or the thermally activated delayed fluorescent material. | 2022-07-14 |
20220220106 | QUINOLINE COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS AND USES THEREOF - Provided are quinoline derivative compounds of Formulae (I), (II) and (III) with an inhibitory effect on mTOR and applications of their pharmaceutically acceptable salts, their stereoisomers, their hydrates or their solvates in preparation of medicine for preventing and/or treating diseases caused by enteroviruses. | 2022-07-14 |
20220220107 | CRYSTAL FORMS OF ACRYLIC ACID DERIVATIVES, PREPARATION METHOD THEREFOR AND USE THEREOF - Crystal forms A, B, C, D, E, F, G and H of a compound represented by formula I and a preparation method therefor, as well as medical uses for the various crystal forms and advantages thereof in various aspects. | 2022-07-14 |
20220220108 | SUBSTITUTED NAPHTHALENE DIIMIDES AND THEIR USE - The present invention relates to naphthalene diimides, NDIs, and methods of synthesising them. The NDIs have DNA-quadruplex binding and stabilising activity, and potential in treatment of pancreatic, prostate, and other human cancers. The NDIs are a compound of Formula I: | 2022-07-14 |
20220220109 | JAK INHIBITOR COMPOUND AND PHARMACEUTICAL COMPOSITION CONTAINING SAME - The present invention relates to a JAK inhibitor compound and a pharmaceutical composition including the same. More specifically, the present invention relates to a compound of Formula I or a pharmaceutically acceptable salt thereof and a pharmaceutical composition including the same. The structure of the compound of Formula I is described in the specification. The compound of the present invention can exhibit therapeutic effects on a variety of diseases, for example, inflammatory diseases, autoimmune diseases, myeloproliferative diseases, and human cancers due to its ability to regulate signal transduction at the level of JAK kinases. | 2022-07-14 |
20220220110 | METHYL- AND TRIFLUOROMETHYL-CONTAINING DISUBSTITUTED SULFONAMIDE SELECTIVE BCL-2 INHIBITOR - Disclosed is a methyl- and trifluoromethyl-containing disubstituted sulfonamide selective BCL-2 inhibitor; specifically disclosed are a compound of formula I, a stereoisomer or pharmaceutically acceptable salt of same, a preparation method therefor, and a pharmaceutical composition comprising the compound. Also disclosed are uses of the compound and of the pharmaceutical composition comprising the compound in treating anti-apoptotic protein BCL-2-related diseases such as cancer. | 2022-07-14 |
20220220111 | 1,8-NAPHTHYRIDINONE COMPOUNDS AND USES THEREOF - 1,8-naphthyridinone compounds as modulators of an adenosine receptor are provided. The compounds may find use as therapeutic agents for the treatment of diseases mediated through a G-protein-coupled receptor signaling pathway and may find particular use in oncology. | 2022-07-14 |
20220220112 | SYNTHESIS OF KEY INTERMEDIATE OF KRAS G12C INHIBITOR COMPOUND - The present invention relates to an improved, efficient, scalable process to prepare intermediate compounds, such as compound 5M, having the structure | 2022-07-14 |
20220220113 | PHOSPHATIDYLINOSITOL 3-KINASE INHIBITORS - The present disclosure provides selective phosphoinositide 3-kinase gamma inhibitors of Formula (I) including (I-a), (I-b), (I-c), and (I-d), or pharmaceutically acceptable salts thereof. These compounds are useful for the treatment of conditions mediated by one or more PI3K isoforms, such as PI3K gamma (PI3Kγ). The present disclosure further provides methods of inhibiting phosphoinositide 3-kinase gamma using these compounds for treatment of disorders related to phosphatidylinositol 3-kinase gamma activity. | 2022-07-14 |
20220220114 | PHOSPHODIESTERASE INHIBITORS AND USE - The invention provides compounds that may inhibits to ENPP1, and are accordingly useful for treatment disorders related to ENPP1. The invention further provides pharmaceutical compositions containing these compounds and methods of using these compounds to treat or prevent disorders related to ENPP1. | 2022-07-14 |
20220220115 | HETEROCYCLIC COMPOUNDS AND USES THEREOF - Heterocyclic compounds as Wee1 inhibitors are provided. The compounds may find use as therapeutic agents for the treatment of diseases and may find particular use in oncology. | 2022-07-14 |
20220220116 | PROTEIN KINASE B INHIBITORS - The invention relates to a novel group of compounds of Formula (I) or salts thereof: | 2022-07-14 |
20220220117 | 9-SUBSTITUTED AMINO TRIAZOLO QUINAZOLINE DERIVATIVES AS ADENOSINE RECEPTOR ANTAGONISTS, PHARMACEUTICAL COMPOSITIONS AND THEIR USE - In its many embodiments, the present invention provides certain 9-substituted amino triazolo quinazoline compounds of the structural Formula (I): | 2022-07-14 |
20220220118 | ION CHANNEL MODULATORS - The present invention is directed to, in part, fused heteroaryl compounds and compositions useful for preventing and/or treating a disease or condition relating to aberrant function of a voltage-gated, sodium ion channel, for example, abnormal late/persistent sodium current. Methods of treating a disease or condition relating to aberrant function of a sodium ion channel including neurological disorders (e.g., Dravet syndrome, epilepsy), pain, and neuromuscular disorders are also provided herein. | 2022-07-14 |
20220220119 | SPIRO-LACTAM NMDA RECEPTOR MODULATORS AND USES THEREOF - Disclosed are compounds having potency in the modulation of NMDA receptor activity. Such compounds can be used in the treatment of conditions such as depression and related disorders. Orally delivered formulations and other pharmaceutically acceptable delivery forms of the compounds, including intravenous formulations, are also disclosed. | 2022-07-14 |
20220220120 | CRYSTAL FORM OF WEE1 INHIBITOR COMPOUND AND USE THEREOF - Disclosed is a crystal form of a compound of formula (I) and the use of the crystal form in the preparation of a drug for treating Wee1-related diseases. | 2022-07-14 |
20220220121 | SOLID FORMS OF ALPHA-1062 GLUCONATE - The invention relates to crystalline forms of Alpha-1062 gluconate. In one aspect, the invention relates to a crystalline solid form of Alpha-1062 gluconate (Form A), wherein said crystalline form has prominent peaks at 3.61, 10.98, 14.41 and 18.44 degrees 2-theta (±0.2) in a powder X-ray diffraction pattern. The invention further relates to methods for manufacturing crystalline forms and compositions comprising said crystalline forms. | 2022-07-14 |
20220220122 | PCSK9 INHIBITORS AND METHODS OF USE THEREOF - The invention relates to novel heteroaryl compounds and pharmaceutical preparations thereof. The invention further relates to methods of treating or preventing cardiovascular diseases, and methods treating sepsis or septic shock, using the novel heterocyclic compounds disclosed herein. | 2022-07-14 |
20220220123 | AMORPHOUS AND CRYSTALLINE FORMS OF RELUGOLIX - The present application relates to crystalline forms R1-R10 of relugolix and process for preparation thereof. The present application also relates to amorphous form and amorphous solid dispersion of relugolix and process for preparation thereof. Crystalline forms R1 are stable under all storage conditions for three months. Crystalline form R1 have excellent physico-chemical properties and may be used conveniently in a pharmaceutical composition comprising relugolix. The application also relates to a process for purification of relugolix. | 2022-07-14 |
20220220124 | NOVEL COMPOUNDS HAVING BET, ESTROGEN RECEPTOR, AND ANDROGEN RECEPTOR DEGRADATION ACTIVITY AND USES THEREOF - Compounds, pharmaceutical compositions containing such compounds, and their use in prevention and treatment of cancer and other related diseases and conditions are disclosed. In an embodiment, the disclosed compounds have the following Formula (I) and pharmaceutically acceptable salts thereof: | 2022-07-14 |
20220220125 | FUSED ISOINDOLIN-1-ONE DERIVATIVES USEFUL AS GRK2 INHIBITORS - The present invention is directed to fused isoindolin-1-one derivatives, pharmaceutical compositions containing them and their use in the treatment of disorders and conditions modulated by GRK2. | 2022-07-14 |
20220220126 | CONDENSED HETEROCYCLIC DERIVATES AS BCL-2 INHIBITORS FOR THE TREATMENT OF NEOPLASTIC DISEASES - The disclosure includes compounds of Formula (A): | 2022-07-14 |
20220220127 | COMPOSITION FOR PHOTOELECTRIC DEVICE, AND PHOTOELECTRIC DEVICE, IMAGE SENSOR, AND ELECTRONIC DEVICE INCLUDING THE SAME - A composition for a photoelectric device includes a p-type semiconductor compound represented by Chemical Formula 1 and an n-type semiconductor compound: | 2022-07-14 |
20220220128 | HETEROCYCLIC COMPOUNDS AS KINASE INHIBITORS, COMPOSITIONS COMPRISING THE HETEROCYCLIC COMPOUND, AND METHODS OF USE THEREOF - (I) Disclosed herein are compounds of formula I, and/or a stereoisomer, a stable isotope, or a pharmaceutically acceptable salt or solvate thereof; and therapeutic uses of these compounds, which are inhibitors of rearranged during transfection (RET), potentially useful in the treatment of RET-associated diseases, such as RET-associated cancers. | 2022-07-14 |
20220220129 | METHOD FOR PRODUCING METAL-ORGANIC FRAMEWORKS - An object of the present invention is to produce a high-quality Metal-Organic Framework in a short time. A method for producing a Metal-Organic Framework according to the present invention includes simultaneously and continuously applying centrifugal force and shear force to a formulation containing a metal ion donor, a multidentate ligand, and a solvent. | 2022-07-14 |
20220220130 | NOVEL BORONIC ESTERS AND METHODS FOR MAKING THE SAME - There is provide herein a compound of Formula (1): | 2022-07-14 |
20220220131 | PROCESS FOR THE GENERATION OF METAL-CONTAINING FILMS - A process including bringing a solid substrate in contact with a compound of general formula (I), (II), (III), or (IV) in the gaseous state | 2022-07-14 |
20220220132 | ORGANOSILANE PRECURSORS FOR ALD/CVD/SOD OF SILICON-CONTAINING FILM APPLICATIONS - Disclosed are methods of deposition a Si-containing layer that comprise:
| 2022-07-14 |
20220220133 | METHOD FOR PRODUCING TRIORGANOSILANE COMPOUND - The invention provides a method for producing a triorganosilane compound which includes (1) a step of reacting a diorganosilane compound represented by the formula (I): | 2022-07-14 |
20220220134 | PHOSPHOHISTIDINE MIMETICS AND ANTIBODIES TO SAME - Provided are phosphonopyrazole-based phosphohistidine analogs that are useful as haptens for the preparation of immunogens, immunogens that include these haptens linked to carrier molecules, antibodies thereto and uses of these antibodies, haptens, immunogens and phosphohistidine analogs. | 2022-07-14 |
20220220135 | HIGHLY SELECTIVE AND POTENT NPP1 INHIBITORS BASED ON URIDINE-5'-P,-DITHIOPHOSPHATE ANALOGUES - The invention relates to a novel highly selective and potent NPP1 inhibitors, compositions comprising such, and their use as pharmaceuticals. | 2022-07-14 |
20220220136 | DINUCLEAR MOLYBDENUM PRECURSORS FOR DEPOSITION OF MOLYBDENUM-CONTAINING FILMS - Dinuclear molybdenum coordination complexes are described. Methods for depositing molybdenum-containing films on a substrate are described. The substrate is exposed to a dinuclear molybdenum precursor and a reactant to form the molybdenum-containing film (e.g., elemental molybdenum, molybdenum oxide, molybdenum carbide, molybdenum silicide, molybdenum nitride). The exposures can be sequential or simultaneous. | 2022-07-14 |
20220220137 | MOLYBDENUM(VI) PRECURSORS FOR DEPOSITION OF MOLYBDENUM FILMS - Molybdenum(VI) coordination complexes are described. Methods for depositing molybdenum-containing films on a substrate are described. The substrate is exposed to a molybdenum precursor and a reactant to form the molybdenum-containing film (e.g., elemental molybdenum, molybdenum oxide, molybdenum carbide, molybdenum silicide, molybdenum nitride). The exposures can be sequential or simultaneous. | 2022-07-14 |
20220220138 | MOLYBDENUM(IV) AND MOLYBDENUM(III) PRECURSORS FOR DEPOSITION OF MOLYBDENUM FILMS - Molybdenum(IV) and molybdenum(III) coordination complexes are described. Methods for depositing molybdenum-containing films on a substrate are described. The substrate is exposed to a molybdenum precursor and a reactant to form the molybdenum-containing film (e.g., elemental molybdenum, molybdenum oxide, molybdenum carbide, molybdenum silicide, molybdenum nitride). The exposures can be sequential or simultaneous. | 2022-07-14 |
20220220139 | MOLYBDENUM (0) PRECURSORS FOR DEPOSITION OF MOLYBDENUM FILMS - Molybdenum(0) coordination complexes comprising ligands which each coordinate to the metal center by nitrogen or phosphorous are described. Methods for depositing molybdenum-containing films on a substrate are described. The substrate is exposed to a molybdenum precursor and a reactant to form the molybdenum-containing film (e.g., elemental molybdenum, molybdenum oxide, molybdenum carbide, molybdenum silicide, molybdenum nitride). The exposures can be sequential or simultaneous. | 2022-07-14 |
20220220140 | ARENE MOLYBDENUM (0) PRECURSORS FOR DEPOSITION OF MOLYBDENUM FILMS - Molybdenum(0) coordination complexes comprising an arene ligand and one or more neutral ligands which coordinate to the metal center by carbon, nitrogen or phosphorous are described. Methods for depositing molybdenum-containing films on a substrate are described. The substrate is exposed to a molybdenum precursor and a reactant to form the molybdenum-containing film (e.g., elemental molybdenum, molybdenum oxide, molybdenum carbide, molybdenum silicide, molybdenum nitride). The exposures can be sequential or simultaneous. | 2022-07-14 |
20220220141 | ORGANIC ELECTROLUMINESCENT MATERIALS AND DEVICES - Provided are organometallic compounds of of Formula I: | 2022-07-14 |
20220220142 | ORGANOMETALLIC COMPOUND, ORGANIC LIGHT-EMITTING DEVICE INCLUDING THE SAME, AND ELECTRONIC APPARATUS INCLUDING THE ORGANIC LIGHT-EMITTING DEVICE - An organometallic compound represented by Formula 1: | 2022-07-14 |
20220220143 | IMPROVED PREPARATION OF CATALYST SYSTEM - Improved preparation process for supported catalyst systems, which comprise a specific class of metallocene complexes in combination with a boron containing cocatalyst and an aluminoxane cocatalyst and use of the new, improved catalyst system. | 2022-07-14 |
20220220144 | MULTIMERIC PAN-SELECTIN ANTAGONISTS - Compounds, compositions, and methods for modulating in vitro and in vivo processes mediated by selectin binding are described herein. For example, multimeric selectin modulators and their use are described, wherein the multimeric selectin modulators comprise a glycomimetic linked to a member of a class of compounds termed BASAs (Benzyl Amino Sulfonic Acids) or a member of a class of compounds termed BACAs (Benzyl Amino Carboxylic Acids). | 2022-07-14 |
20220220145 | CYCLIC PHOSPHATE COMPOUNDS - Provided herein are cyclic phosphate compounds, their preparation and their uses, such as treating liver diseases or conditions or a disease or condition in which the physiological or pathogenic pathways involve the liver. | 2022-07-14 |
20220220146 | MORPHIC FORMS OF 4-AMINO-7-(3,4-DIHYDROXY-5-(HYDROXYMETHYL)TETRAHYDROFURAN-2-YL)-2-METHYL-- 7H-PYRROLO[2,3-d]PYRIMIDINE-5-CARBOXAMIDE AND USES THEREOF - The present disclosure relates to crystalline morphic forms of 4-amino-7-((2R,3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl) tetrahydrofuran-2-yl)-2-methyl-7H-pyrrolo[2,3-d]pyrimidine-5-carboxamide. The morphic form can be a stable hemihydrate crystalline form. | 2022-07-14 |
20220220147 | CD73 INHIBITORS - Described herein are CD73 inhibitors and pharmaceutical compositions comprising said compounds. The subject compounds and compositions are useful for the treatment of cancer, infections, and neurodegenerative diseases. | 2022-07-14 |
20220220148 | METHODS AND COMPOSITIONS FOR STIMULATION OF THE INTESTINAL ENTEROENDOCRINE SYSTEM FOR TREATING DISEASES OR CONDITIONS RELATED TO THE SAME - This invention relates to methods of stimulating the activity of the human and animal enteric nervous system. The method comprises orally administering an aminoserol, such as squalamine, a naturally occurring aminosterol isolated from | 2022-07-14 |
20220220149 | SOLID STATE FORMS OF SAGE-217 AND PROCESSES FOR PREPARATION THEREOF - The present disclosure encompasses solid state forms of SAGE-217, in embodiments SAGE-217:Oxalic acid Co-crystal, processes for preparation thereof, and pharmaceutical compositions thereof. | 2022-07-14 |
20220220150 | COMPOSITIONS AND METHODS FOR TREATING CNS DISORDERS - Described herein are neuroactive steroids of the Formula (I): | 2022-07-14 |
20220220151 | METHOD FOR PREPARING PEPTIDES - A method for preparing peptides is disclosed, the method comprising a step of forming a peptide bond wherein the carboxyl group of a first amino acid or first peptide is activated and an amino group of the first activated amino acid or first peptide is protected by a protecting group having a water-solubility enhancing group and the activated carboxyl group of the first amino acid or first peptide is reacted with an amino group of a second amino acid or second peptide wherein said carboxyl group of the first amino acid or first peptide is activated in the absence of the second amino acid or second peptide. Peptides comprising a protecting group having a water-solubility enhancing group being bound to the amino group and an activated or free carboxyl group are also disclosed. | 2022-07-14 |
20220220152 | BIVALENT ANTAGONISTS OF INHIBITORS OF APOPTOSIS PROTEINS - The present technology is directed to compounds, compositions, and methods related to treatment of cancers and viral infections mediated by IAPs, e.g., compounds of Formula I (including Formulas IA, IB, IC, ID, IE, IF, and IG), a stereoisomer thereof, or a pharmaceutically acceptable salt of the compound or the stereoisomer of the compound. In particular, the present compounds and compositions may be used to treat IAP-mediated ovarian cancer and hepatitis B infection. | 2022-07-14 |
20220220153 | B-CATENIN/B-CELL LYMPHOMA 9 PROTEIN-PROTEIN INTERACTION INHIBITING PEPTIDOMIMETICS - Disclosed herein is a series of helical sulfono-γ-AApeptides that mimic the binding mode of the α-helical HD2 domain of B-Cell Lymphoma 9 (BCL9). As disclosed herein, sulfono-γ-AApeptides can structurally and functionally mimic the α-helical domain of BCL9, and selectively disrupt β-catenin/BCL9 PPIs with even higher potency. More intriguingly, these sulfono-γ-AApeptides can enter cancer cells, bind with β-catenin and disrupt β-catenin/BCL PPI, and exhibit excellent cellular activity, which is much more potent than the BCL9 peptide. Furthermore, enzymatic stability studies demonstrated the remarkable stability of the helical sulfono-γ-AApeptides, with no degradation in the presence of pronase for 24 h, augmenting their biological potential. | 2022-07-14 |
20220220154 | POLYPEPTIDES INCLUDING A BETA-TRICALCIUM PHOSPHATE-BINDING SEQUENCE AND USES THEREOF - Provided herein are polypeptides that include one or more β-tricalcium phosphate (βTCP)-binding sequence(s) and uses thereof. | 2022-07-14 |
20220220155 | VASCULAR CHOLESTEROL INHIBITORS AND USE THEREOF - The present invention relates to compounds having pharmacological activity in the treatment of vascular cholesterol accumulation, plasma low-density lipoproteins (LDL) abnormal aggregation and/or inhibition or reduction of the formation of VSMC foam cells, processes for their preparation, pharmaceutical compositions comprising them, and their use in therapy and/or prophylaxis of conditions wherein decrease of vascular cholesterol accumulation, inhibition of LDL aggregation, inhibition or reduction of the formation of VSMC foam cells and/or prevention of aggregated LDL (agLDL) internalization is useful such as atherosclerosis, coronary artery disease, stroke, peripheral artery disease, angina pectoris, thrombosis, hyperlipidemia, hyperlipoproteinemia type II, familial hypercholesterolemia, familial combined hyperlipidemia, type II diabetes, hypothyroidism, Cushing's syndrome and obesity. | 2022-07-14 |
20220220156 | Shape-Responsive Nanostructures - Provided herein are single-stranded tile (SST) structures prepared from and comprising single-stranded γPNA (ss-γPNA) strands, along with methods of making an SST structure from single-stranded γPNA (ss-γPNA) strands. | 2022-07-14 |
20220220157 | ADENOVIRUS POLYNUCLEOTIDES AND POLYPEPTIDES - There is provided inter alia an isolated polynucleotide, wherein the polynucleotide encodes a polypeptide selected from the group consisting of:
| 2022-07-14 |
20220220158 | SOLUBLE AND IMMUNOREACTIVE FLAVIVRAL NS1 POLYPEPTIDES - The disclosure relates to a polypeptide suitable for detecting antibodies against a flavivirus in an isolated biological sample having a flavivirus NS1 wing domain specific amino acid sequence, wherein no amino acid sequences from the NS1 β-ladder domain of said flavivirus are present in the polypeptide. In an embodiment, the flavivirus is selected from Zika virus (ZIKV), West-Nile virus (WNV), Dengue virus types 1-4 (DENV1-4), tick-borne encephalitis virus (TBEV), yellow fever virus (YFV) and Japanese encephalitis virus (JEV). Also disclosed is a method for producing said flaviviral NS1 wing domain specific polypeptides, a method for detecting antibodies specific for a first flavivirus species, the use of said flaviviral NS1 wing domain specific polypeptides for detecting antibodies as well as a reagent kit for detecting said flavivirus antibodies that has a flavivirus NS1 wing domain polypeptide. | 2022-07-14 |
20220220159 | FIMH MUTANTS, COMPOSITIONS THEREWITH AND USE THEREOF - Polypeptides comprising a FimH lectin domain comprising at least one an amino acid mutation that causes the FimH lectin domain to be in the low affinity conformation for mannose are described. Pharmaceutical compositions which comprise such polypeptides and methods of stimulating an immune response in a subject in need thereof by administration of the polypeptide are further described. | 2022-07-14 |
20220220160 | NOVEL INSECT INHIBITORY PROTEINS - Pesticidal proteins exhibiting toxic activity against Lepidopteran pest species are disclosed, and include, but are not limited to, TIC13085 and TIC13087. DNA constructs are provided which contain a recombinant nucleic acid sequence encoding one or more of the disclosed pesticidal proteins. Transgenic plants, plant cells, seed, and plant parts resistant to Lepidopteran infestation are provided which contain recombinant nucleic acid sequences encoding the pesticidal proteins of the present invention. Methods for detecting the presence of the recombinant nucleic acid sequences or the proteins of the present invention in a biological sample, and methods of controlling Lepidopteran species pests using any of the TIC13085 and TIC13087 pesticidal proteins are also provided. | 2022-07-14 |
20220220161 | Constitutive Yeast LLP Promotor-Based Expression Systems - The present invention belongs to the field of biotechnology, recombinant protein production, molecular biology, microbiology and microbial genetics. It provides a modified eukaryotic cell that is modified to the effect that the modified eukaryotic cell is not able to provide an SSN6-like related protein or an SSN6-like protein that exerts its wildtype function and/or wildtype activity, the amount of SSN6-like related protein or of SSN6-like protein being present in the modified eukaryotic cell differs from the amount of SSN6-like related protein or of SSN6-like protein being present in its wildtype form, and/or essentially no SSN6-like related protein or SSN6-like protein is present in the modified cell. Additionally, the present invention provides a polynucleotide sequence comprising a modified ssn6-like related gene or modified ssn6-like gene, and a vector comprising said polynucleoptide. Additionally provided is an expression vector comprising a promoter that is repressed in the presence of SSN6-like protein or SSN6-like related protein, and a host cell comprising said vectors. The present invention further refers to a method for determining the purity of a composition by using the modified eukaryotic cell, to a method of expressing gene(s) of interest, and eukaryotic cells comprising modified ssn6-like related gene or ssn6-like gene. | 2022-07-14 |
20220220162 | TARGETED DELIVERY OF THE ABRIN-A A-CHAIN TO CANCER CELLS - A targeted delivery of recombinant therapeutic protein to inhibit the growth of cancer cells is disclosed. The recombinant protein derived from Abrin-a A-chain able to inhibit the growth of cancer cell and conjugated to stxB to form Abrin-f-stxB. The abrin toxin A chain and the Shiga toxin B chain are linked with the furin linker to form a recombinant therapeutic protein as chemotherapeutic agent to inhibit the growth of cancer cells. A conjugate for the delivery of a compound into cancer cells, comprising a first module mediates cell targeting and facilitates cellular uptake, a second module facilitates transport to the endoplasmic reticulum (ER), a third module mediates translocation from the ER to the cytosol and a compound that is desired to be delivered to the cytosol. The recombinant protein Abrin-f-stxB exhibits high binding affinity of stxB as a drug delivery system to Gb3 receptor in targeted cancer diagnosis and treatment. | 2022-07-14 |
20220220163 | RECOMBINANT DEAMIDATED GLIADIN POLYPEPTIDE ANTIGEN, RECOMBINANT ANTIGEN-EXPRESSING GENE, RECOMBINANT EXPRESSION VECTOR, AND PREPARATION METHOD AND APPLICATION THEREOF - A recombinant deamidated gliadin polypeptide antigen, a recombinant antigen-expressing gene, a recombinant expression vector, a preparation method therefor, and an application thereof. The recombinant deamidated gliadin polypeptide antigen comprises a DGP-1 peptide, an interleukin 15 protein, and a DGP-2 peptide. The amino acid sequence of the DGP-1 peptide is as shown in SEQ ID NO. 1, and the amino acid sequence of the DGP-2 peptide is as shown in SEQ ID NO 2. The recombinant deamidated gliadin polypeptide antigen has good sensitivity, high specificity, and low preparation costs in the detection of celiac disease, allows determination of IgG-DGP antibodies in serum, and especially enables diagnosis for potential patients with celiac disease among patients with IgA deficiency and infant population. | 2022-07-14 |
20220220164 | A GENETICALLY ENCODED PROTEIN SYNTHESIS INHIBITOR - The present invention relates to an expression system for a genetically encoded protein synthesis inhibitor containing RNA N-glycosidase activity split into two components. The expression system can be combined with genetic targeting systems to achieve cell- and/or tissue-type-specific and/or temporally-specific control of protein synthesis in a host, particularly in a mammalian host. | 2022-07-14 |
20220220165 | MASS PRODUCTION SYSTEM OF RECOMBINANT BAGWORM SILK PROTEIN - Provided is a gene expression reinforcement system for a recombinant bagworm fibroin H chain protein. The system includes a gene encoding a modified recombinant bagworm fibroin H chain protein in which either the N-terminal domain or the C-terminal domain constituting the recombinant bagworm fibroin H chain protein has been partially or entirely deleted. | 2022-07-14 |
20220220166 | PPR PROTEIN CAUSING LESS AGGREGATION AND USE OF THE SAME - In order to improve aggregation property of a PPR protein, the A | 2022-07-14 |
20220220167 | COMPOSITIONS AND METHODS RELATING TO NOVEL SULFONO-gamma-AA PEPTIDES - Provided herein are compounds, compositions, pharmaceutical compositions, kits, and methods relating to novel sulfono-γ-AA peptides. Novel sulfono-γ-AA peptides as described herein can have the structure according to Formula 1: | 2022-07-14 |
20220220168 | INTERFERON REGULATORY FACTOR 5 INHIBITORS AND USES THEREOF - Polypeptides comprising a cell penetrating amino acid sequence and an interferon regulatory factor 5 (IRF5) targeting amino acid sequence are disclosed, where the IRF5 targeting amino acid sequence is one or more of RHATRHG (SEQ ID NO:1), KSRDFRL (SEQ ID NO:2) and GPRDMPP (SEQ ID NO:3), as well as methods of using these polypeptides to treat diseases, such as autoimmune and inflammatory diseases. | 2022-07-14 |
20220220169 | Modular Therapeutics for the Treatment of Inflammatory Diseases and Cancer - Compositions and methods to regulate immune responses by fusing Complement Control Protein domains and extra-cellular Complement Receptor domains to a scaffold through flexible linkers for treatment of immunological diseases and disorders oar described. | 2022-07-14 |
20220220170 | AAV CAPSID CHIMERIC ANTIGEN RECEPTORS AND USES THEREOF - Aspects of the disclosure relate to compositions and methods for modulating the immune response of a subject (e.g., a human subject) to certain viral antigens (e.g., antigens derived from AAV capsid proteins). The disclosure is based, in part, on isolated nucleic acids and expression constructs encoding chimeric antigen receptors (CARs) that target AAV capsid proteins, and recombinant immune cells comprising such constructs (e.g., recombinant T-cell comprising a CAR (CAR T-cells), and recombinant T-regulatory cells comprising a CAR (CAR T-regs)). | 2022-07-14 |
20220220171 | CELL PERMEABLE PROTEINS FOR GENOME ENGINEERING - The present disclosure provides genome engineering proteins, e.g., nucleic acid binding domains and/or functional domains that have a net positive charge and are cell permeable and can be introduced into the cells without the use of a carrier such as micelles, vesicles, liposomes, and the like. | 2022-07-14 |
20220220172 | PROGRANULIN VARIANTS - Provided herein are progranulin variants and fusion proteins that comprise a progranulin variant and an Fc polypeptide. Methods of using such proteins to treat progranulin-associated disorders (e.g., a neurodegenerative disease, such as frontotemporal dementia (FTD)) are also provided herein. | 2022-07-14 |
20220220173 | TDP-43 MITOCHONDRIAL LOCALIZATION INHIBITOR FOR THE TREATMENT OF NEUROGENERATIVE DISEASE - A method of treating a neurodegenerative disease in a subject includes administering to the subject a therapeutically effective amount of a TDP-43 mitochondrial localization inhibitor. | 2022-07-14 |
20220220174 | BNIP3 PEPTIDES FOR TREATMENT OF REPERFUSION INJURY - The invention provides peptides capable of inhibiting the individual activity and inter-pathway communication of BNIP3, BAX and mitochondria. The peptides can be used in methods of treating a disease or condition in a subject in which it is desirable to prevent cell damage and cell death. | 2022-07-14 |
20220220175 | NOVEL CANCER ANTIGENS AND METHODS - There are disclosed inter alia polypeptides and nucleic acids encoding said polypeptides which are useful in the treatment, prevention and diagnosis of cancer, particularly melanoma, especially cutaneous melanoma and uveal melanoma. | 2022-07-14 |
20220220176 | POLYETHYLENE GLYCOL-MODIFIED FORM OF HEPATOCYTE GROWTH FACTOR OR ACTIVE FRAGMENT THEREOF - A variant of a hepatocyte growth factor or an active fragment thereof reduces the liver tropism and selectively exert bioactivity in a target tissue in disease other than a liver tissue. A polyethylene glycol-modified form of a hepatocyte growth factor or an active fragment thereof has polyethylene glycol(s) bound to (a) terminus(es) of the hepatocyte growth factor or the active fragment thereof via (a) protease-sensitive peptide(s). | 2022-07-14 |
20220220177 | MODIFIED HUMAN ERYTHROPOIETIN - A modified human erythropoietin with an increased plasma half-life, with an erythropoietic activity of less than 0.5% in relation to a native erythropoietin, which maintains the neuroprotective and neuroplastic capacity, which comprises the mutation of at least one of the binding sites the homodimeric or heterodimeric receptor by incorporating consensus sites for N-glycosylation. | 2022-07-14 |
20220220178 | Compositions for Treatment of Vascular Disease - Provided are various embodiments relating to compositions and methods for treating vascular disease, including core NOX1 promoters and variants thereof for regulating expression of transgenes in response to vascular pathology and allowing for increased transgene loading capacity. Also provided are variant FOXP polypeptides having a zinc finger and leucine zipper region of a different FOXP polypeptide. Further provided are vectors comprising the core NOX1 promoters and/or a coding sequence for variant FOXP polypeptides described herein and optionally coding sequence(s) for one or more additional therapeutic polypeptide(s), such as IL10, for treating inflammation-associated diseases, such as vascular disease. Also provided is a screening model for testing therapeutic agents capable of treating established and ongoing atherosclerotic pathology. | 2022-07-14 |
20220220179 | FUSION PROTEIN COMPRISING IL13 - The invention is concerned with a fusion protein comprising interleukin 13 and a regulatory cytokine, for example, an interleukin chosen from interleukin 4, interleukin 10, interleukin 27, interleukin 33, transforming growth factor beta 1, transforming growth factor beta 2, and interleukin 13, a nucleic acid molecule encoding such fusion protein, a vector comprising such nucleic acid molecule, and a host cell comprising such nucleic acid molecule or such vector. The invention further pertains to a method for producing such fusion protein. The fusion protein or a gene therapy vector encoding the fusion protein may be used in the prevention or treatment of a condition characterized by pathological pain, chronic pain, neuro-inflammation and/or or neurodegeneration. | 2022-07-14 |
20220220180 | NOVEL METHOD - The invention relates to a method of expanding a population of regulatory T cells in a tissue or organ of a subject, wherein said method comprises administration of IL-2 and a targeting moiety specific for said tissue or organ, and wherein said tissue or organ is the central and/or peripheral nervous system. The invention further relates to populations of regulatory T cells produced according to the method and the production of said population in vivo. Also provided is a pharmaceutical composition comprising IL-2 and a targeting moiety as defined herein as well as a method of treating a disease or disorder mediated by inflammation or for the reduction of inflammation which comprises the methods defined herein or administration of a pharmaceutical composition as defined herein. | 2022-07-14 |
20220220181 | SEPARATION MOIETIES AND METHODS OF USE THEREOF - Provided herein are separation moieties that are suitable for use in conjunction with a variety of therapeutic payloads. The separation moieties serve to generate conditionally active macromolecules whereby the macromolecules have reduced or minimal biological activity until the separation moieties are modified under specific conditions. | 2022-07-14 |
20220220182 | NOVEL IL2 AGONISTS AND METHODS OF USE THEREOF - The present disclosure relates to IL2 agonists with improved therapeutic profiles. | 2022-07-14 |
20220220183 | COMPOSITIONS AND METHODS RELATING TO THE TREATMENT OF DISEASES - The present invention relates to compositions and methods for promoting the induction of a cell-mediated immune response (such as that mediated by Th1 cells) and the suppression of a humoral or allergic immune response (such as that mediated by Th2 and Th17 cells). In particular, the invention relates to compositions and methods for preventing or treating allergy, such as food allergy, and associated allergic diseases, and conditions where an exaggerated Th17 response plays a detrimental role, such as inflammatory responses and autoimmune diseases. The invention further extends to the use of the compositions of the invention in the treatment and/or prophylaxis of allergy and associated allergic diseases and also of cancer. | 2022-07-14 |
20220220184 | INTERFERON ALPHA 2B VARIANTS - The present invention provides a fusion polypeptide comprising a first domain and a second domain, wherein the first domain comprises a polypeptide ligand which binds to a cell surface-associated antigen and the second domain comprises aglycosylated interferon α 2b (IFNα2b) having a sequence of SEQ ID NO: 1 or SEQ ID NO: 2. The aglycosylated IFNα2b further comprises one or more amino acid substitutions or deletions which attenuate the activity of the aglycosylated IFNα2b. | 2022-07-14 |
20220220185 | METHOD AND SYSTEM FOR PREDICTING COUPLING PROBABILITIES OF G-PROTEIN COUPLED RECEPTORS WITH G-PROTEINS - Disclosed is a Designer Receptor Exclusively Activated by Designer Drugs (DREADD), and an amino acid sequence for determining coupling or no coupling between G-protein and G-protein coupled receptor (GPCR) mediated by a GPCR ligand in a cell based assay. | 2022-07-14 |
20220220186 | CHIMERIC CO-STIMULATORY PROTEINS COMPRISING MUTANT INTRACELLULAR DOMAINS WITH INCREASED EXPRESSION - The present application relates to functionally optimized intracellular co-stimulatory domains, optionally in combination with cell-intrinsic immune checkpoint inhibitory receptors or immune-stimulatory receptors or portions thereof, which can be used in adoptive cell therapy to treat human diseases and disorders. | 2022-07-14 |
20220220187 | CHIMERIC RECEPTOR THERAPY - A non-naturally occurring polynucleotide encoding a miRNA that inhibits the expression of an immune checkpoint protein. The polynucleotide may further encode a chimeric receptor, a cytokine, and/or a cell tag. A vector comprising the aforementioned polynucleotide. A modified immune effector cell comprising the aforementioned polynucleotide. Compositions and kits comprising the aforementioned polynucleotide and/or cell. A method for treating a subject suffering from a disease or disorder, comprising administering the aforementioned cell to a subject in need thereof. The use of the aforementioned cell in the manufacture of a medicament for the treatment of a disease or disorder. A method for the detection of a disease or disorder associated with the overexpression of an antigen in a subject. A method for the treatment of a disease or disorder comprising the serial administration of polynucleotides encoding a chimeric antigen receptor or a cell comprising the same. | 2022-07-14 |
20220220188 | COMPOSITIONS AND METHODS OF CHIMERIC ALLOANTIGEN RECEPTOR T CELLS - The invention includes compositions comprising at least one chimeric alloantigen receptor (CALLAR) specific for an alloantibody, vectors comprising the same, compositions comprising CALLAR vectors packaged in viral particles, and recombinant T cells comprising the CALLAR. The invention also includes methods of making a genetically modified T cell expressing a CALLAR, wherein the expressed CALLAR comprises a Factor VIII or fragment thereof extracellular domain. | 2022-07-14 |
20220220189 | COMPOSITIONS AND METHODS FOR TREATMENT OF HEMOCHROMATOSIS - This application provides polynucleotides comprising a coding sequence for a functionally active hereditary hemochromatosis protein (HFE) or a functionally active fragment thereof. The invention further provides compositions comprising said polynucleotides and their use in methods of preventing or treating hemochromatosis in a subject. | 2022-07-14 |
20220220190 | A YEAST-FERMENTED RECOMBINANT FIBRONECTIN PEPTIDE IN SMALL MOLECULE, AND ITS PREPARATION METHOD AND APPLICATIONS THEREOF - The invention discloses a yeast-fermented recombinant fibronectin peptide in small molecule, comprising at least one β subunit binding domain of sodium-potassium ATPase, wherein the amino acid sequence of the β subunit binding domain of sodium-potassium ATPase is shown in SEQ ID NO: 2. The invention also discloses a preparation method for the yeast-fermented recombinant fibronectin peptide in small molecule and applications of the yeast-fermented recombinant fibronectin peptide in small molecule. The yeast-fermented recombinant fibronectin peptide in small molecule of the present invention can be effectively absorbed by a skin, and has excellent healing and repairing effects on traumatic skin lesions or subcutaneous lesions with intact keratin. | 2022-07-14 |
20220220191 | METHOD FOR IMPROVING AFFINITY OF ANTIBODY FOR ANTIGEN AND USE THEREOF - The present invention relates to a method for improving affinity of an antibody for an antigen. The present invention relates to a method for producing an antibody with improved affinity for an antigen as compared to an unmodified antibody. The present invention relates to a modified antibody with improved affinity for an antigen as compared to an unmodified antibody. | 2022-07-14 |
20220220192 | ANTI-ALPHA-SYNUCLEIN ANTIBODIES - The present invention relates to antibodies binding alpha synuclein and fragments thereof capable of binding alpha synuclein as a monomer and in fibrils and preventing alpha synuclein aggregation induced by alpha synuclein fibrils. The antibodies of the present invention are for use in the treatment of alpha synucleinopathies, including Parkinson's disease. | 2022-07-14 |
20220220193 | ANTI-APOC3 ANTIBODIES AND METHODS OF USE THEREOF - The instant disclosure provides antibodies that specifically bind to ApoC3 (e.g., human ApoC3) and antagonize ApoC3 function. Also provided are pharmaceutical compositions comprising these antibodies, nucleic acids encoding these antibodies, expression vectors and host cells for making these antibodies, and methods of treating a subject using these antibodies. | 2022-07-14 |
20220220194 | METHODS AND AGENTS FOR THE TREATMENT OF OCULAR DISEASE - This disclosure relates generally to methods and agents for treating an ocular disease or disorder. More particularly, the present disclosure relates to the use of CD14 antagonist antibodies for treating an ocular disease or disorder. | 2022-07-14 |
20220220195 | ANTIBODY TO HUMAN IL-1 BETA - The present invention relates to anti-IL-1 beta binding members and in particular to monovalent high potency IL-1 beta-binding antibody fragments being highly stable and soluble. Such binding members may be used in the treatment of inflammatory and other diseases as well as in diagnostics. Also provided are related nucleic acids, vectors, cells, and compositions. | 2022-07-14 |
20220220196 | ANTIBODY FORMULATION - Symptoms of atopic dermatitis in a human subject are reduced by administering to the subject a pharmaceutical composition that includes a pharmaceutically acceptable carrier and a therapeutically effective amount of an agent that selectively binds IL-1α. | 2022-07-14 |
20220220197 | Cancer Treatment by Targeting Plexins in the Immune Compartment - The invention relates to compounds inhibiting plexin-A2 and/or plexin-A4, with said compounds specifically targeting plexin-A2 and/or plexin-A4 on or in CD8-positive (CD8+) T-cells. Medical uses of such compounds are also part of the invention. | 2022-07-14 |